Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin... REVIEW Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia Charles L. Bennett, MD, PhD Context The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepo- Samuel M. Silver, MD, PhD etin are licensed to treat chemotherapy-associated anemia in patients with nonmy- eloid malignancies. Although systematic overviews of trials have identified venous throm- Benjamin Djulbegovic, MD, PhD boembolism (VTE) risks, none have identified mortality risks with ESAs. Athena T. Samaras, BA Objective To evaluate VTE and mortality rates associated with ESA administration C. Anthony Blau, MD for the treatment of anemia among patients with cancer. Kara J. Gleason, BS Data Sources A published overview from the Cochrane Collaboration (search dates: January 1, 1985-April 1, 2005) and MEDLINE and EMBASE databases (key words: clini- Sara E. Barnato, MD cal trial, erythropoietin, darbepoetin, and oncology), the public Web site of the US Kathleen M. Elverman Food and Drug Administration and ESA manufacturers, and safety advisories (search D. Mark Courtney, MD dates: April 1, 2005-January 17, 2008). June M. McKoy, MD, MPH, JD Study Selection Phase 3 trials comparing ESAs with placebo or standard of care for the treatment of anemia among patients with cancer. Beatrice J. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/venous-thromboembolism-and-mortality-associated-with-recombinant-ZN3RayP53S
Publisher
American Medical Association
Copyright
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.299.8.914
pmid
18314434
Publisher site
See Article on Publisher Site

Abstract

REVIEW Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia Charles L. Bennett, MD, PhD Context The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepo- Samuel M. Silver, MD, PhD etin are licensed to treat chemotherapy-associated anemia in patients with nonmy- eloid malignancies. Although systematic overviews of trials have identified venous throm- Benjamin Djulbegovic, MD, PhD boembolism (VTE) risks, none have identified mortality risks with ESAs. Athena T. Samaras, BA Objective To evaluate VTE and mortality rates associated with ESA administration C. Anthony Blau, MD for the treatment of anemia among patients with cancer. Kara J. Gleason, BS Data Sources A published overview from the Cochrane Collaboration (search dates: January 1, 1985-April 1, 2005) and MEDLINE and EMBASE databases (key words: clini- Sara E. Barnato, MD cal trial, erythropoietin, darbepoetin, and oncology), the public Web site of the US Kathleen M. Elverman Food and Drug Administration and ESA manufacturers, and safety advisories (search D. Mark Courtney, MD dates: April 1, 2005-January 17, 2008). June M. McKoy, MD, MPH, JD Study Selection Phase 3 trials comparing ESAs with placebo or standard of care for the treatment of anemia among patients with cancer. Beatrice J.

Journal

JAMAAmerican Medical Association

Published: Feb 27, 2008

References